CN115887602A - Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine applying device - Google Patents
Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine applying device Download PDFInfo
- Publication number
- CN115887602A CN115887602A CN202211556055.1A CN202211556055A CN115887602A CN 115887602 A CN115887602 A CN 115887602A CN 202211556055 A CN202211556055 A CN 202211556055A CN 115887602 A CN115887602 A CN 115887602A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- hole
- pharmaceutical composition
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 180
- 208000009608 Papillomavirus Infections Diseases 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000011068 loading method Methods 0.000 claims abstract description 13
- 238000012377 drug delivery Methods 0.000 claims abstract 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 11
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 11
- 241001313857 Bletilla striata Species 0.000 claims description 11
- 240000009138 Curcuma zedoaria Species 0.000 claims description 11
- 240000007643 Phytolacca americana Species 0.000 claims description 11
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 11
- 229940116229 borneol Drugs 0.000 claims description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 241001071917 Lithospermum Species 0.000 claims description 9
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 9
- 235000011837 pasties Nutrition 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 229940107666 astragalus root Drugs 0.000 claims description 5
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 3
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 235000019509 white turmeric Nutrition 0.000 claims description 3
- 241000118825 Alkanna tinctoria Species 0.000 claims description 2
- 241000157511 Oldenlandia Species 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 14
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 6
- 210000003679 cervix uteri Anatomy 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 206010008263 Cervical dysplasia Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- CAULGCQHVOVVRN-UHFFFAOYSA-N (3Z,9E)-Germacra-3,7(11),9-trien-6-on Natural products CC(C)=C1CC=C(C)CCC=C(C)CC1=O CAULGCQHVOVVRN-UHFFFAOYSA-N 0.000 description 1
- CAULGCQHVOVVRN-SWZPTJTJSA-N (E,E)-germacrone Chemical compound CC(C)=C1C\C=C(C)\CC\C=C(C)\CC1=O CAULGCQHVOVVRN-SWZPTJTJSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- ZVSZHMFUICOVPY-UHFFFAOYSA-N Germacrone Natural products CC(=C)C1CC=C(/C)CCC=C(/C)CC1=O ZVSZHMFUICOVPY-UHFFFAOYSA-N 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for resisting papillomavirus infection, a preparation method and a medicine applying device, and solves the technical problems that the existing traditional Chinese medicine composition for resisting papillomavirus infection is relatively complex in formula and inconvenient to use. The traditional Chinese medicine raw materials of the pharmaceutical composition comprise the following components: the drug delivery device is used for delivering the drug composition, and comprises a drug loading tube and a drug feeder.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for resisting papillomavirus infection, a preparation method and a medicine applying device.
Background
Persistent infection of high-risk papillomavirus (HR-HPV) in female genital tract is closely related to the progression of high-grade squamous intraepithelial lesion (HSIL) of cervix to invasive cervical cancer, so that reduction of persistent infection rate of HPV virus and blocking of Cervical Intraepithelial Neoplasia (CIN) disease development are necessary, and are difficult and important points of clinical treatment and follow-up.
At present, western medicine clinical treatment mainly aims at regular follow-up of interferon or no medicine for cervical HR-HPV infection, LEEP operation or hysterectomy treatment is mostly adopted for patients suffering from HSIL, few western medicines capable of resisting continuous HPV infection with evidence-based medical evidence are proved through clinical research tests, and the problems of long treatment period, low virus negative turning rate, high medicine resistance, high recurrence rate, high cost and the like exist in the application process of the drug therapy, so that the drug therapy is controversial.
In order to overcome a plurality of defects of western medicines in treatment, the research on the application of a traditional Chinese medicine preparation with smaller side effect and low price to resisting papillomavirus infection has important significance, in the existing traditional Chinese medicine research technology, although a plurality of traditional Chinese medicine compositions for resisting papillomavirus infection are developed, the formula is relatively complex, and the use is inconvenient.
Therefore, it is necessary to develop a new formula of traditional Chinese medicine composition aiming at the deficiency of the traditional Chinese medicine composition for resisting papillomavirus infection and solve the problem of inconvenient use.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: the existing traditional Chinese medicine composition for resisting papillomavirus infection has a relatively complex formula and is inconvenient to use.
The invention is realized by the following technical scheme:
the pharmaceutical composition for resisting papillomavirus infection, wherein the raw materials of the medicinal materials comprise the following components: raw astragalus root, oldenlandia, bletilla striata, zedoary, pokeberry root, alkanna tinctoria and borneol.
The invention has the advantages that the organic combination of 7 medicines is adopted, the prescription is simple, and the treatment principle is as follows: strengthening body resistance, removing toxic substances, removing blood stasis, and promoting granulation.
In the prescription, astragalus root has the functions of tonifying qi and invigorating yang, expelling toxin and pus, healing sore and promoting granulation, oldenlandia diffusa, the two medicines for tonifying qi and clearing toxin are monarch medicines, bletilla striata and lithospermum have the functions of cooling blood and activating blood circulation, and removing necrotic tissue and promoting granulation are ministerial medicines, pokeberry root and curcuma zedoary have the functions of activating blood circulation, removing stasis, inducing diuresis, reducing swelling and resolving masses and are adjuvant medicines, borneol has the functions of removing necrotic tissue and promoting granulation, and reducing swelling and relieving pain, and the whole formula has the functions of tonifying qi, clearing toxin, activating blood and promoting granulation.
Astragalus has the functions of enhancing the immunity of organisms, improving the phagocytic capacity of phagocytes, increasing the number of leucocytes of peripheral blood vessels and the like, zedoary root contains more effective anticancer and antiviral components, such as germacrone, curcumenol, curcumene and the like, the components have the functions of resisting inflammation, relieving pain, removing necrotic tissue and promoting granulation, and not only can resist free-form viruses, but also have the inhibiting effect on virus gene segments integrated on the chromosome of host cells. The borneol has good anti-inflammatory and analgesic effects, and the pokeberry root, the bletilla striata, the lithospermum, the oldenlandia diffusa and the like also have the effects of anti-inflammation, antivirus, anti-tumor, immunity regulation and the like.
The invention discloses a preferable pharmaceutical composition for resisting papillomavirus infection, which comprises the following raw materials in parts by weight:
3-5 parts of raw astragalus membranaceus, 3-5 parts of spreading hedyotis herb, 1-3 parts of bletilla striata, 1-3 parts of curcuma zedoary, 1-3 parts of pokeberry root, 1-3 parts of lithospermum and 0.2-1.0 part of borneol.
According to the invention, through reasonable taking of the components, various traditional Chinese medicine components have a synergistic effect on a proper drug effect, wherein the dosage of monarch drugs is larger, and the monarch drugs, the adjuvant drugs and the adjuvant drugs are used for realizing the synergistic effect, so that the curative effect is good, and the treatment course is short.
The invention discloses a preferable pharmaceutical composition for resisting papillomavirus infection, which comprises the following raw materials in parts by weight:
4 parts of raw astragalus root, 4 parts of oldenlandia diffusa, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
On the basis of determining the component types, a large amount of dosage design comparison is carried out, and the dosage combination effect is the best.
The preparation method of the pharmaceutical composition for resisting papillomavirus infection comprises the following steps:
step 1: weighing the traditional Chinese medicine raw materials;
and 2, step: uniformly mixing the Chinese medicinal raw materials in the step 1 and crushing into Chinese medicinal superfine powder of 300-400 meshes;
and 3, step 3: adding a small amount of distilled water into the Chinese medicinal micropowder to obtain a paste.
The invention relates to a medicine applying device, which is used for applying medicine to a medicine composition.
The invention preferably discloses a medicine feeding device which comprises a medicine filling pipe and a medicine feeder, wherein the medicine filling pipe is filled with the medicine composition, and when medicine is fed, the medicine filling pipe is inserted into the medicine feeder which is then inserted into a vagina for use.
The medicine loading pipe plays a role in storing the medicine composition, and when medicine feeding is needed, the medicine loading pipe is inserted into the medicine feeder and the medicine is loaded to an affected part from the medicine feeder.
The medicine feeding device is preferred, the medicine loading tube comprises a tube body and a tube head, a limiting portion and a medicine through hole are formed in the tube head, the limiting portion is connected with the tube body, the medicine through hole penetrates through the limiting portion and is communicated with the tube body, the medicine through hole is closed when medicine compositions are stored, the medicine through hole is opened when the medicine compositions are used, and the tube head is inserted into the medicine feeder to extrude the medicine compositions into the medicine feeder.
The medicine feeding device preferably comprises a medicine feeding head and a bag body, the medicine feeding head is connected with the front end of the bag body, a through hole is formed in the tail portion of the bag body, the size of the limiting portion is larger than that of the through hole, the limiting portion of the pipe head penetrates through the through hole to enter the bag body when medicine is fed, the limiting portion is clamped at the through hole, the medicine filling pipe can be connected with the medicine feeding device, then the medicine composition in the medicine filling pipe is pasted and extruded into the medicine feeding device, and the paste medicine is extruded to an affected part.
The invention preferably discloses a medicine feeding device, wherein a plurality of spray holes are formed in the medicine feeding head.
Furthermore, the front and the side of the medicine feeding head are provided with a plurality of spray holes.
The spray holes can enable the pasty medicine to reach an affected part through the spray holes under the action of pressure when a bag body of the medicine feeder is extruded, the spray holes on the front side can enable the medicine to be sprayed to the cervix, and the spray holes on the side surface can enable the medicine to be sprayed to the side wall of the vagina.
Further, the used material of body of charge pipe is made for translucent PP material, spacing portion adopts soft silica gel to make.
Spacing portion that soft silica gel made has elasticity, when entering into the medicine feed ware through the through-hole, can warp the entering, and after getting into, can automatic recovery original shape to when the extrusion utricule, atmospheric pressure has the extrusion to the through-hole and makes spacing portion have airtight effect to the through-hole.
The number of the front spray holes is less than that of the side spray holes, and the medicine is easier to spray due to the fact that the spraying paths of the front spray holes are shorter and more direct, so that the number of the spray holes is less than that of the side spray holes, the difference between the spraying amount of the front spray holes and that of the side spray holes is convenient to reduce, and the spraying is more uniform.
The invention has the following advantages and beneficial effects:
1. the Chinese medicinal preparation can regulate the immunologic function of organisms and inhibit viruses, thereby achieving the aim of strengthening the body resistance, promoting Th1/Th2 to restore the balance state, changing the immunologic state of the vagina, resisting tumors and viruses and providing a favorable environment for the transformation of cervical lesions to normal tissues. The traditional Chinese medicine has obvious advantages due to the characteristics of small toxic and side effects, high patient acceptance and capability of improving cervical complications and local immune microenvironment in the vagina.
2. The pharmaceutical composition of the invention has significant and stable effects on the treatment of HPV infection; the traditional Chinese medicine has the advantages of few medicinal herbs, simple preparation process, short treatment course, low cost, no toxic or side effect and suitability for wide popularization.
3. The invention designs a device special for applying the medicine, and has good medicine applying effect and good applicability.
Drawings
The accompanying drawings, which are included to provide a further understanding of the embodiments of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the principles of the invention. In the drawings:
FIG. 1 is a block diagram of the applicator of the present invention with the applicator and feeder separated.
Fig. 2 is a structural diagram of the combined medicine loading device and the medicine feeder of the medicine loading device.
Fig. 3 is a structural schematic view of the medicine feeder of the invention.
The component names in the drawings are as follows:
1-medicine loading tube, 10-tube body, 11-limiting part, 12-medicine through hole, 2-medicine feeder, 20-medicine feeding head, 21-bag body, 22-through hole and 23-spray hole.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples and accompanying drawings, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not meant to limit the present invention.
Example 1
1. Preparing traditional Chinese medicine raw materials according to the following weight:
4 parts of raw astragalus membranaceus, 4 parts of spreading hedyotis herb, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
2. The preparation process comprises the following steps:
step 1: weighing the traditional Chinese medicine raw materials;
step 2: uniformly mixing the traditional Chinese medicine raw materials in the step 1 and crushing the mixture into traditional Chinese medicine ultrafine powder of 300-400 meshes;
and step 3: adding small amount of distilled water into the Chinese medicinal micropowder to obtain paste.
Example 2
The difference between this example and example 1 is that the amount of the Chinese medicinal materials is different as follows:
3 parts of raw astragalus membranaceus, 3 parts of spreading hedyotis herb, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
Example 3
The difference between this example and example 1 is that the amount of the Chinese medicinal materials is different as follows:
4 parts of raw astragalus root, 4 parts of oldenlandia diffusa, 1 part of bletilla striata, 1 part of curcuma zedoary, 1 part of pokeberry root, 1 part of lithospermum and 0.2 part of borneol.
Although examples 1, 2 and 3 are all effective, the effect of example 1 is better in terms of strengthening the body resistance and removing toxicity, and removing blood stasis and promoting tissue regeneration, and example 1 is selected for clinical experiments as follows.
Clinical experiments
1.1 general data
1.1.1 subject: 300 patients with HR-HPV, meeting the diagnosis standard of Western medicine infection; positive detection of cervical high-risk papilloma virus;
subject selection criteria: women in childbearing age with irregular menstrual cycle, non-pregnant period and lactation period. Similar drugs to this study were not used for nearly 3 months; patients with cervical cancer are excluded, and patients with blood coagulation dysfunction, chronic inflammation of mental and nervous systems and other systems, or immune system diseases are excluded.
The traditional Chinese medicine composition is randomly divided into three groups, wherein each group comprises 100 patients, and the age, the disease condition and the disease course among the groups have no significant difference and are comparable.
1.2 methods of treatment:
(1) treatment groups: the medicine is prepared according to the prescription of the embodiment 1, the medicine applying device is adopted for spraying 0.8-1g of medicine into the cervix and the vagina every time, 1 month/10 times/1 course of treatment, every other day is adopted for one time, 3 courses of treatment are totally carried out, and medicine is stopped in the menstrual period.
(2) Control group: interferon alpha-2 b gel, 1g of the drug of example 1 was applied to the cervix and vagina each time for 1 month/10 times/1 treatment period, once every other day for 3 treatment periods, with drug withdrawal during the menstrual period.
(3) Follow-up blank group: no drug intervention was accepted, appropriate exercise was ordered, physical fitness was enhanced, and follow-up observation was performed for 3 months.
1.3 detection indices and methods
1.3.1 factor detection and data processing
All subjects underwent cervical HR-HPV detection before (week 0) and 3 months after group entry, respectively: detecting the currently known 18 high-risk HPV DNA by adopting a 2 nd generation hybrid capture (HC-II) technology, and taking the measured RLU/CO value as a virus load result; meanwhile, the HPV E6/E7 mRNA detection kit is used for detecting 18 high-risk HPV E6/E7 mRNAs by adopting a branched-chain DNA technology (branch-DNA, bDNA).
1.3.2 evaluation criteria for therapeutic Effect
And (3) healing: HR-HPV virus is completely negative; the effect is shown: the HPV virus is reduced in number or viral load compared with the type before treatment, but is not totally turned negative; and (4) invalidation: the HPV virus persists without turning negative.
1.4 statistical treatment: statistical analysis using SPSS 24.0 software
2 results and analysis
The results of HR-HPV turning negative after different treatment periods were observed for three groups of patients. The statistics of 2 cases of interferon groups and 5 cases of blank groups show that the negative conversion rate of HPV after 3 months of the traditional Chinese medicine treatment group is 89.00 percent (89/100), the interferon control group is 55.10 percent (54/98), and the blank follow-up group is 37.89 percent (36/95). The negative conversion rate of the traditional Chinese medicine is obviously higher than that of the other two groups, and the difference has statistical significance (P < 0.05).
Example 4
As shown in fig. 1, 2 and 3, a medicine feeding device for go up the medicine to pharmaceutical composition, including charge pipe 1 and medicine feeder 2, charge pipe 1 includes body 10 and tube head, be provided with spacing portion 11 and medicine through hole 12 on the tube head, spacing portion 11 with body 10 connects, medicine through hole 12 runs through spacing portion 11 just medicine through hole 12 communicates with each other with body 10, when storing pharmaceutical composition, medicine through hole 12 is airtight, when using pharmaceutical composition, opens medicine through hole 12, just the tube head inserts in extruding medicine feeder 2 with pharmaceutical composition in the medicine feeder 2, medicine feeder 2 includes medicine feed head 20 and utricule 21, medicine head 20 with the front end of utricule 21 is connected, the afterbody of utricule 21 is provided with through-hole 22, the size of spacing portion 11 of charge pipe 1 is greater than through-hole 22, when going up the medicine, spacing portion 11 of tube head passes through-hole 22 enters into utricule 21, spacing portion 11 is located at through-hole 22 for paste feed pipe 1 can insert paste feed pipe 2 with medicine feed pipe 2 in the affected part, then extrude medicine feed pipe 2 through medicine into paste feed pipe 2, the vagina.
The loading tube 1 plays a role of storing the pharmaceutical composition, and when the administration is required, the loading tube 1 is inserted into the medicine feeder 2 and the medicine is applied to the affected part from the medicine feeder 2.
The front and the side of the medicine feeding head 20 are provided with a plurality of spray holes 23.
The spray holes 23 are arranged to allow the pasty medicine to reach the affected part through the spray holes 23 under the pressure when the capsule body 21 of the medicine feeder 2 is squeezed, the spray holes 23 on the front side allow the medicine to be sprayed to the cervix, and the spray holes 23 on the side allow the medicine to be sprayed to the side wall of the vagina.
The used material of body 10 of charge pipe 1 is made for translucent PP material, spacing portion 11 adopts soft silica gel to make.
The capsule body 20 of the medicine feeder 2 is made of translucent PP material.
Spacing portion 11 that soft silica gel made has elasticity, when entering into medicine feed ware 2 through-hole 22, can warp and get into, and when getting into the back, can resume original shape automatically to when extruding utricule 21, atmospheric pressure has the extrusion to through-hole 22 and makes spacing portion 11 have airtight effect to through-hole 22, and the pasty medicine of being convenient for is spout from orifice 23, and it is convenient to go up the medicine.
The number of the spray holes 23 on the front surface is less than that of the spray holes 23 on the side surface, and the medicine is easier to spray because the spray path of the spray holes 23 on the front surface is shorter and more direct, so that the spray holes 23 are less than that on the side surface, the difference between the spray amount on the front surface and the spray amount on the side surface is convenient to reduce, and the spraying is more uniform.
After the medicine feeding head 20 of the medicine feeder 2 is inserted into the vagina, pasty medicines are sprayed out by pressing the capsule body 21, the medicine can be sprayed on the cervix and the side wall of the vagina at one time, and the medicine feeder is convenient and efficient.
The medicine loading device is a disposable packaging tube, when medicines are stored, the end part of the medicine through hole 12 is sealed to prevent the medicines from being wetted, so that a patient can take the medicine home to use, and when the medicines need to be loaded, the medicine through hole 12 needs to be cut off and then inserted into the medicine feeder 2.
The medicine feeder 2 of the present invention is reusable and can be sterilized with alcohol before use.
The using method comprises the following steps:
firstly, the medicine through hole 12 of the medicine feeding pipe 1 is cut off, so that the medicine through hole 12 is communicated with the outside, then the pipe head is inserted into the capsule body 21 of the medicine feeder 2 through the through hole 22 of the medicine feeder 2, as shown in fig. 2, at the moment, the pipe body 10 of the medicine feeding pipe 1 is extruded, pasty medicines enter the capsule body 21 of the medicine feeder 2 under the pressure effect, the medicine feeding head 20 of the medicine feeder 2 is inserted along the vagina, the capsule body 21 is pressed, and the pasty medicines are sprayed out along the spray holes 23 under the pressure effect.
The above-mentioned embodiments, objects, technical solutions and advantages of the present invention are further described in detail, it should be understood that the above-mentioned embodiments are only examples of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. The pharmaceutical composition for resisting papillomavirus infection is characterized in that the raw materials of the medicinal materials comprise the following components: raw astragalus root, oldenlandia, bletilla striata, zedoary, pokeberry root, alkanna tinctoria and borneol.
2. The pharmaceutical composition for resisting papillomavirus infection according to claim 1, wherein the raw materials of the medicinal materials consist of the following components in parts by weight:
3-5 parts of raw astragalus membranaceus, 3-5 parts of spreading hedyotis herb, 1-3 parts of bletilla striata, 1-3 parts of curcuma zedoary, 1-3 parts of pokeberry root, 1-3 parts of lithospermum and 0.2-1.0 part of borneol.
3. The pharmaceutical composition for resisting papillomavirus infection according to claim 1 or 2, wherein the raw materials of the medicinal materials consist of the following components in parts by weight:
4 parts of raw astragalus membranaceus, 4 parts of spreading hedyotis herb, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
4. The preparation method of the pharmaceutical composition for resisting papillomavirus infection is characterized by comprising the following steps:
step 1: weighing the traditional Chinese medicinal raw materials as defined in any one of claims 1 to 3;
step 2: uniformly mixing the Chinese medicinal raw materials in the step 1 and crushing into Chinese medicinal superfine powder of 300-400 meshes;
and step 3: adding small amount of distilled water into the Chinese medicinal micropowder to obtain paste.
5. A dosing device for dosing a pharmaceutical composition according to claims 1-3 or a pasty pharmaceutical product prepared according to claim 4.
6. A drug delivery device according to claim 5, characterized by comprising a drug loading tube (1) and a drug feeder (2), wherein the drug loading tube (1) contains the drug composition, and the drug loading tube (1) is inserted into the drug feeder (2) during drug delivery.
7. The medicine feeding device according to claim 6, wherein the medicine feeding tube (1) comprises a tube body (10) and a tube head, a limiting portion (11) and a medicine through hole (12) are formed in the tube head, the limiting portion (11) is connected with the tube body (10), the medicine through hole (12) penetrates through the limiting portion (11) and the medicine through hole (12) is communicated with the tube body (10), when the medicine composition is stored, the medicine through hole (12) is closed, when the medicine composition is used, the medicine through hole (12) is opened, and the tube head is inserted into the medicine feeding device (2).
8. The medicine feeding device according to claim 7, wherein the medicine feeder (2) comprises a medicine feeding head (20) and a bag body (21), the medicine feeding head (20) is connected with the front end of the bag body (21), a through hole (22) is formed in the tail part of the bag body (21), and the pipe head is inserted into the through hole (22) during medicine feeding.
9. A drug delivery device as claimed in claim 7 or 8, wherein the drug delivery head (20) is provided with a plurality of orifices (23).
10. A drug delivery device as claimed in claim 8, characterised in that the front and side faces of the head (20) are provided with a plurality of orifices (23).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211556055.1A CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211556055.1A CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115887602A true CN115887602A (en) | 2023-04-04 |
| CN115887602B CN115887602B (en) | 2024-01-26 |
Family
ID=86470898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211556055.1A Active CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115887602B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
-
2022
- 2022-12-06 CN CN202211556055.1A patent/CN115887602B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
Non-Patent Citations (1)
| Title |
|---|
| 卢雯平等: "益气活血解毒中药联合树突状细胞疫苗 对荷瘤小鼠免疫抑制的调控", 中国中医药信息杂志, vol. 20, no. 3, pages 46 - 48 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115887602B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN108478922A (en) | A kind of section office of gynemetrics vaginal administration device | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101637561A (en) | Fritillary-loquat medicinal composition and preparation method thereof | |
| CN100500135C (en) | Medicine for treating menstrual irregularities and menalgia | |
| CN1857668A (en) | Chloasma treating Chinese medicine preparation | |
| CN101837100A (en) | Medicinal composition for curing gynecopathy and application thereof | |
| CN102940822B (en) | Synovitis treating medicine and preparation method thereof | |
| CN102274417B (en) | Chinese prepared medicament for treating aplastic anemia | |
| CN115887602A (en) | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine applying device | |
| CN101979031B (en) | Medicament for treating hemorrhoids and preparation method thereof | |
| CN104435484A (en) | Seven connected traditional Chinese medicine packets for treating colorectal cancer | |
| CN101112584A (en) | Chinese traditional medicine compound preparations and method for preparing the same and use thereof | |
| CN101332282A (en) | Traditional Chinese medicine composition for treating gynecologic diseases reduced by kidney deficiency and genitals coldness | |
| CN210873672U (en) | Push-rod type vagina medicine feeder for treating gynecological diseases | |
| CN103301415B (en) | Medicinal composition for preventing and treating intrauterine adhesion after induced abortion operation and application thereof | |
| CN1277573C (en) | Medication for curing ulcerationd of oral cavity | |
| WO2022047729A1 (en) | Anti-diarrheal suppository traditional chinese medicine composition, and preparation method therefor and use thereof | |
| CN206950449U (en) | Comprehensive topical application of drug cervical plug | |
| CN105327219B (en) | A kind of Chinese medicine composition and preparation method thereof for treating female pelvic cavity inflammation | |
| CN101190297B (en) | Traditional Chinese medicine compound preparations for preventing and controlling abnormal uterine bleeding after medical abortion | |
| CN1943657B (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN106943506B (en) | A pharmaceutical composition for treating climacteric syndrome, and its preparation method | |
| CN100482253C (en) | Preparation with antler gelatin and epimeddium for treating mammary gland hyperplasia and preparation method thereof | |
| CN1454616A (en) | Medicine for curing haemorrhoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |